Development of anti-cancer vaccines. The technology combines a promising tumour antigen with a powerful vaccine vector to provide a specific immunotherapy.
The project addresses the need for improved toxicity assays for better risk assessment to reduce the number of animals used to test toxins and toxic effects. These assays will be developed as kits for commercial availability.
For some patients, voice production after laryngectomy is impossible.For others voice quality is unpredictable or poor to enable high-quality voice production for those patients, a voice-producing shunt prosthesis will be developed.
Based on cannabis metabolomics, cannabis smoke-analysis and advanced extraction techniques, tailor-made well-defined extractions will be made for different medical applications and new techniques for oral admin will be developed.
Research on innovative hrs-pharma tech. For drug development, based on rapid high resolution screening (hrs) of mixtures with thousands of compounds, resulting in more and higher quality drug candidates and allowing research into 'awkward' pharmaceutical targets.
Bioactive alginates (low guluronate) to be produced in-vivo in bacteria, and by in-vitro epimerisation of high mannuronate alginates from seaweed or bacteria. They will be used for wound healing, health supportive fish feed, fish vaccines and also combined with biopolymers for enhanced performance.
To develop a robust point of care test for monitoring the effect of cancer therapy, based on antibodies directed to a patented peptide involved in cell proliferation.
The photochemical internalisation (pci) technology will be used for site-specific enhancement of the therapeutic effect of anti-cancer drugs in a clinical trial on patients with head, neck and other types of cancer
The project will develop a new technology platform integrating photonic crystals with new laser technology using gan. To illustrate the power of the technology, we will develop a prototype of a new medical device for early detection of cancer.
Together with the lgtc lab at the lumc and the bradley group at the university of edinburgh, flexgen wishes to develop a technology platform for oligonucleotide synthesis. This platform enables multiple core-labs around the world to manufacture low-cost arrays for research purposes.